CLARENCE, N.Y.–(BUSINESS WIRE)–22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction and smoking cessation products, announced that Dr. Michael Moynihan, Vice President of Research & Development, will present a poster today on the company’s proprietary BRAND B cigarette at the 66th Tobacco Science Research Conference (TSRC) being held in Concord, North Carolina
Slated for submission to the U.S. Food and Drug Administration (FDA) as a modified risk candidate, BRAND B is reportedly the world’s lowest tar-to-nicotine ratio cigarette. Unlike low tar/low-nicotine brands on the market (previously labeled “light” or “ultra-light” before these descriptors were banned in the U.S. by the Tobacco Control Act in 2010), the nicotine yield of BRAND B is not reduced.
Studies of smokers using low tar-to-nicotine (LTN) research cigarettes such as BRAND B have demonstrated that smoking behavior changes and the dose of smoke inhaled by the smoker including “tar” is significantly reduced (Russell MAH 2000). Specifically, compensatory smoking (e.g., more and/or larger puffs per cigarette) of LTN research cigarettes is greatly curtailed.
Dr. Moynihan’s poster, Effect of Smoking Low Tar-to-Nicotine Ratio Cigarettes on Smoke Exposure, explains that incorporating tobacco with a higher-than-typical nicotine content, LTN cigarettes can be made with lower yields of harmful and potentially harmful smoke constituents while maintaining nicotine yields per cigarette similar to popular full-flavor brands. As announced in April 2012, utilizing studies of exposure to smoke constituents and consumer perception, 22nd Century will submit a modified risk cigarette application for BRAND B to the FDA.
Leading U.S. brands have an average tar-to-nicotine ratio of approximately 13 – meaning that approximately 13 parts “tar” is inhaled for every part nicotine. LTN cigarettes with a tar-to-nicotine ratio of 7 or less have the potential to reduce smoke exposure by 50 percent. If smoke inhalation with LTN cigarettes is reduced by 50 percent on average, confirmed by biomarkers in exposure studies, reduced harm is expected. 22nd Century’s CEO, Joseph Pandolfino explained, “A cigarette that reduces smoke exposure by an average of 50 percent is effectively a hybrid of a zero-tar e-cigarette and a Marlboro® Gold. How much would smoking-related disease decrease in the U.S. if all the cumulative smoke inhaled by smokers were cut in half?”Joseph Pandolfino asks a question that is hard to ignore.
A 50% reduction in exposure to carcinogenic materials is a good place to start. It may not be an e-cigarette, but for those of us committed smokers who are not attracted to e-cigarettes (or to snus, pellets, or lozenges for that matter, etc..), a 50% reduction is a hell of an improvement; therefore, it is of paramount importance that THR (Tobacco Harm Reduction), defines its objective as one that is inclusive to all of the relevant possibilities. This means that combustible cigarettes need to be a part of the overall equation when it comes to reducing the adverse health effects from smoking.
One another note, I was pleasantly surprised to hear that Dr. Gio Batta Gori (of whom I have been a fan of for awhile now) appeared as a keynote speaker at last September's meeting for 22nd Century's shareholders:
Separately, one of the original proponents of LTN cigarettes, Dr. Gio Batta Gori, Director of the Health Policy Center in Bethesda, Maryland, will present a keynote address at 22nd Century Group’s annual shareholder meeting at 2:00 pm on Thursday, September 20, 2012. To be held in Clarence, New York, the annual meeting will be open to company shareholders, select guests, and the media. Dr. Gori will speak on the compelling reasons for less harmful cigarettes and their likely significance to the cigarette industry and the entire tobacco economy.I would have liked to be there to hear what Dr. Gori had to say about Brand B. I'm certain that we will be hearing more from him on this pertinent issue, for the potential to save (and improve upon) the lives of so many smokers like myself is on the horizon.
Dr. Gori is also author of Virtually Safe Cigarettes: Reviving an Opportunity Once Tragically Rejected and a contributor to national research and prevention agendas at the U.S. National Cancer Institute, where he was deputy director of the Division of Cancer Cause and Prevention and director of the Smoking and Health Program. The latter aimed at developing reduced risk cigarettes, an effort for which Dr. Gori received the Superior Service Award of the U.S. Public Health Service.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company whose proprietary technology allows for the level of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and breeding. 22nd Century owns or is the exclusive licensee of 105 issued patents in 78 countries plus an additional 38 pending patent applications. Hercules Pharmaceuticals, LLC and Goodrich Tobacco Company, LLC are subsidiaries of 22nd Century focused on the company’s (i) prescription smoking cessation aid in development, X-22, and (ii) potential modified risk cigarettes, respectively.
For additional information, please visit: www.xxiicentury.com22nd Century Press Release - September 10 2012.pdf (application/pdf Object)